Interview: Mallinckrodt Deal Golden For Silence Therapeutics
Executive Summary
The gene silencing specialist has signed a collaboration that CEO David Horn Solomon tells Scrip will help push Silence up among its peers in the RNAi space.
You may also be interested in...
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
AstraZeneca Likes Sound Of Silence's Science
The UK major is getting access to Silence's small interfering RNA (siRNA) platform while the London-based biotech is getting further validation of its technology and a considerable pile of cash.
Biopharma Quarterly Dealmaking Statistics, Q3 2019
During Q3, biopharma company fundraising reached $13.3bn, mostly from follow-on public offerings, which again made up the most of those dollars. Despite numerous deals valued at $100m+, M&A activity was the lowest of the year. Many of the biggest partnership deals were centered around the inflammation/immune area.